Showing 4361-4370 of 5771 results for "".
- Norlase Receives CE Mark Approval for LION Green Laser Systemhttps://modernod.com/news/norlase-receives-ce-mark-approval-for-lion-green-laser-system/2478718/Norlase announced that it has been granted the European CE Mark for the LION green laser system. LION combines the Keeler Vantage Plus diagnostic indirect with Norlase’s compact laser technology into one device. With LION’s untethered and portable design, physicians can move freely between treatm
- AsclepiX Therapeutics Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for DMEhttps://modernod.com/news/asclepix-therapeutics-doses-first-patient-in-phase-1-2a-trial-of-axt107-intravitreal-self-forming-gel-depot-peptide-for-dme/2478717/AsclepiX Therapeutics announced that the first patient has been dosed in the phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity of AXT107 in patients with diabetic macular edema (DME). “Dosing the first patient with AXT107 shortly after the acceptance of its IND is a si
- Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbanceshttps://modernod.com/news/ocuphire-pharma-initiates-lynx-1-phase-3-study-investigating-nyxol-in-night-vision-disturbances/2478713/Ocuphire Pharma announced the initiation of patient recruitment and screening in late December for its LYNX-1 phase 3 registration study evaluating the safety and efficacy of Nyxol in night vision disturbances (NVD) at multiple sites in the US. NVD, also known as dim light vision disturban
- Hi-Health Launches New Eye Care Divisionhttps://modernod.com/news/hi-health-launches-new-eye-care-division/2478716/Hi-Health announced the launch of its new eye care division. “Our mission is to support eye care professionals and their patients with a complete line of products under the Vista brand. Even though Vista
- Samsara Vision Appoints Three New Members to the Board of Directorshttps://modernod.com/news/samsara-vision-appoints-three-new-members-to-the-board-of-directors/2478712/Samsara Vision, a developer of visual prosthetic devices for patients living with late-stage age-related macular degeneration (AMD), has announced the appointment of three new members to its Board of Directors: Jonathan H. Talamo, MD; Tracy M. Valorie; and David Schiff, joining Thierry Clidiere,
- Vision Innovation Partners Completes 17th Acquisition, Eyes of Yorkhttps://modernod.com/news/vision-innovation-partners-completes-17th-acquisition-eyes-of-york/2478708/Vision Innovation Partners announced that it has acquired Eyes of York, an ophthalmology practice in York, Pennsylvania. The acquisition strengthens Vision Innovation Partners’ presence in the
- VisionQuest Biomedical Gains FDA 510(k) Clearance for the Image Quality Analyzer Softwarehttps://modernod.com/news/visionquest-biomedical-gains-fda-510k-clearance-for-the-image-quality-analyzer-software/2478706/VisionQuest Biomedical announced that the company has received 510(k) clearance from the FDA to market the Image Quality Analyzer (IQA) software, which reduces unreadable images captured in teleretinal screening programs by retinal photographers. The IQA is a software system intended for u
- Nicox’s Partner Ocumension Therapeutics Initiates Zerviate Phase 3 Clinical Trial in Chinahttps://modernod.com/news/nicoxs-partner-ocumension-therapeutics-initiates-zerviate-phase-3-clinical-trial-in-china/2478704/Nicox SA announced that its partner, Ocumension Therapeutics, has initiated a phase 3 clinical trial in China with Zerviate, the first and only topical ocular formulation of the anti
- Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombihttps://modernod.com/news/eyenovia-submits-nda-to-fda-for-pharmacologic-mydriasis-with-mydcombi/2478701/Eyenovia announced that it has submitted a new drug application (NDA) to the FDA for MydCombi, a fixed combination mydriatic (pupil dilation) agent. If approved, MydCombi would be the first microdosed ocular therapeutic with a high precision smart delivery system. The NDA submission follow
- Conbercept Treatment of Wet AMD Completes 36-Week Primary Endpoint Visits of Phase 3 Trialhttps://modernod.com/news/conbercept-treatment-of-wet-amd-completes-36-week-primary-endpoint-visits-of-phase-3-trial/2478698/China-based Chengdu Kanghong Pharmaceutical Group announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, d